MPM Oncology Impact Management as of Dec. 31, 2020
Portfolio Holdings for MPM Oncology Impact Management
MPM Oncology Impact Management holds 13 positions in its portfolio as reported in the December 2020 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| TCR2 Therapeutics Common | 18.3 | $104M | 3.4M | 30.93 | |
| Repare Therapeutics Common (RPTX) | 14.4 | $82M | 2.4M | 34.30 | |
| iTeos Therapeutics Common (ITOS) | 14.0 | $80M | 2.4M | 33.82 | |
| Oncorus Common | 13.5 | $77M | 2.4M | 32.33 | |
| Harpoon Therapeutics Common | 11.4 | $65M | 3.9M | 16.61 | |
| Turning Point Therapeutics Common | 6.6 | $38M | 309k | 121.85 | |
| MEI Pharma Common | 4.7 | $27M | 10M | 2.64 | |
| G1 Therapeutics Common | 4.5 | $26M | 1.4M | 17.99 | |
| Epizyme Common | 4.4 | $25M | 2.3M | 10.86 | |
| ADC Therapeutics Common (ADCT) | 3.0 | $17M | 540k | 32.01 | |
| YmAbs Therapeutics Common (YMAB) | 2.9 | $17M | 337k | 49.51 | |
| Merus Common (MRUS) | 2.2 | $12M | 701k | 17.53 | |
| Autolus Therapeutics Common (AUTL) | 0.1 | $355k | 40k | 8.93 |
